Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$40.08M, compared with -$3.32M a year earlier.

Context

  • Net debt amounted to 55.9% of total assets at the end of Q1 FY2026, up 48.8 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -1105.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.08M-9.1% QoQ
Last fiscal yearDec 2025
-$36.72M-403.4% YoY
Year agoMar 2025
-$3.32M-1105.6% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1105.6%——
1 year-403.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(36.72M) USD
Year-over-year change
-403.4%

Net Debt vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -1105.6% is the 7th highest of 8, against a peer median of -136.6%.
  • Net debt amounts to 55.9% of total assets for FRX.TO, versus a peer median of 11.6%.
FRX.TO Competitors
Net Debt for FRX.TO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TSND.TOTerrAscend Corp.Mar 2026$214.88M USD-0.8%-9.8%39.1%
HBP.TOHelix BioPharma Corp.Apr 2026-CA$2.48M CAD-247.3%—11.6%
DR.TOMedical Facilities CorporationMar 2026-$29.12M USD-641.1%-47.8%10.5%
FRX.TOFennec Pharmaceuticals Inc.Mar 2026-$40.08M USD-1105.6%—55.9%
PRN.TOProfound Medical Corp.Mar 2026-$42.86M USD-3.2%—58.3%
OGI.TOOrganiGram Holdings Inc.Mar 2026-CA$45.75M CAD-1155.4%—8.8%
EPRX.TOEupraxia Pharmaceuticals Inc.Mar 2026-$56.53M USD-106.3%—38.9%
WEED.TOCanopy Growth CorporationMar 2026-CA$85.97M CAD-136.6%—7.7%
Peer median (excluding FRX.TO) —-136.6%-28.8%11.6%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.1M23.77M13.27M26.63M36.72M
Short-term Investments00000
Net Receivables01.55M8.81M12.88M23.18M
Inventory0576K2.16M1.06M1.56M
Other Current Assets253K63K44K466K1.37M
Total Current Assets22.39M26.73M26.86M44.12M66.56M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00002.79M
Tax Assets00000
Other Non-current Assets27K211K6K822K710.62K
Total Non-current Assets27K211K6K822K3.5M
Total Assets22.41M26.94M26.86M44.95M70.07M
Account Payables777K2.39M3.78M3.24M4.63M
Short-term Debt00000
Tax Payables00000
Deferred Revenue000248K247.55K
Other Current Liabilities0000(10.25K)
Total Current Liabilities1.65M4.61M7.55M6.92M10.5M
Long-term Debt4.99M24.9M30.93M19.34M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000024.56M
Other Non-current Liabilities00024.56M0
Total Non-current Liabilities4.99M24.9M30.93M43.9M24.52M
Total Liabilities6.64M29.51M38.49M50.82M35.02M
Common Stock140.8M142.59M144.31M145.61M189.56M
Retained Earnings(179.49M)(203.2M)(219.25M)(219.68M)(229.36M)
Accumulated OCI1.24M1.24M1.24M1.24M1.24M
Other Stockholders Equity00000
Minority Interest00000
Total Equity15.77M(2.57M)(11.62M)(5.87M)35.05M
Total Debt4.99M24.9M30.95M19.34M0
Net Debt(16.11M)1.13M17.69M(7.29M)(36.72M)

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.